跳至主要内容
临床试验/NCT07735767
NCT07735767已完成不适用

Tdap Vaccination During Pregnancy or Postpartum and Lactation-Related Outcomes

HealthPartners Institute0 个研究点目标入组 36,245 人开始时间: 2014年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
36,245
主要终点
Infant growth - failure to thrive (Subgroup Pregnancy)

研究概览

简要总结

A retrospective cohort study based on the secondary use of pre-existing data. The study assesses the association between antenatal and postpartum maternal Tdap vaccination and select infant and lactation-related outcomes.

详细描述

Since 2012, the United States Advisory Committee on Immunization Practices has recommended administering the Tdap (tetanus, diphtheria, acellular pertussis) vaccine during every pregnancy, ideally between 27 and 36 gestational weeks, to reduce pertussis morbidity and mortality in young infants. Although the safety of Tdap during pregnancy for maternal and birth outcomes is well-documented, there are very limited data on lactation-related outcomes following Tdap vaccination.

This is a novel study of antenatal and postpartum Tdap vaccination and select adverse infant and lactation-related outcomes in mother-infant pairs to address the need for comprehensive safety data. Study specific aims:

Aim 1: To assess associations between receipt of Tdap vaccine in pregnancy and the risk of adverse infant and lactation-related outcomes.

Aim 2: To assess associations between receipt of Tdap vaccine postpartum and the risk of adverse infant and lactation-related outcomes among women who are breastfeeding in the 3 months postpartum.

No investigational vaccines will be administered in this study. Participants will be included in the study on the basis of their having received Tdap vaccine as part of routine care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
16 Years 至 49 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • The study includes pregnant women aged 16-49 years at delivery who had a live-birth delivery between 01 January 2014 (01 June 2018 for one site given data availability) and 31 December 2022, received prenatal care within the participating health systems before 6 months gestation, had a gestational age at delivery of at least 27 weeks, and linked to an infant with a WCV before 2 months of age within the participating health systems.

排除标准

  • We excluded those with Tdap vaccination before the recommended gestational age of 27 gestational weeks. For postpartum analyses, we excluded those who did not initiate human milk feeding or where human milk feeding information was not available.

结局指标

主要结局

Infant growth - failure to thrive (Subgroup Pregnancy)

时间窗: 3 months (91 days) to 12 months of age

Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy and up to 90 days after delivery

Infant growth - failure to thrive (Subgroup Postpartum)

时间窗: 3 months (91 days) to 12 months of age

Among patients who did not discontinue human milk feeding on or before 90 days after delivery. Exposure: Any Tdap 0 to 90 days after delivery Comparator: No Tdap 0 to 90 days after delivery

Infant health care utilization - Number of infant outpatient visits up to 6 months of age (Subgroup Pregnancy)

时间窗: 0 to 6 months after delivery

Count of unique dates of outpatient visits in the 6 months after delivery. Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy and up to 90 days after delivery

Infant health care utilization - Number of infant outpatient visits in the 90 days after index date (Subgroup Postpartum )

时间窗: up to 6 months: 90-day window for vaccination plus 90-day window for outcome assessment

Among patients who did not discontinue human milk feeding before index date (ie, vaccination or pseudovaccination date), count of unique dates of outpatient visits in the 90 days after vaccination or pseudovaccination. Exposure: Any Tdap 0 to 90 days after delivery Comparator: No Tdap 0 to 90 days after delivery

Infant health care utilization - Number of infant emergency department visits up to 6 months of age (Subgroup Pregnancy)

时间窗: 0 to 6 months after delivery

Count of unique dates of emergency department visits in the 6 months after delivery. Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy and up to 90 days after delivery

Infant health care utilization - Number of infant emergency department visits in 90 days after index date (Subgroup Postpartum)

时间窗: Up to 6 months: 90-day window for vaccination plus 90-day window for outcome assessment.

Among patients who did not discontinue human milk feeding before index date (ie, vaccination or pseudovaccination date), count of unique dates of emergency department visits in the 90 days after vaccination or pseudovaccination. Exposure: Any Tdap 0 to 90 days after delivery Comparator: No Tdap 0 to 90 days after delivery

Human milk feeding initiation vs no initiation (Subgroup Pregnancy)

时间窗: 0 to 12 months

Any or exclusive human milk versus formula only or no human milk feeding documented during follow up. Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy

Any human milk feeding vs none around the 2-month Well Child Visit (WCV) (Subgroup Pregnancy)

时间窗: 42 to 104 days after delivery

Any human milk versus formula only or no human milk feeding documented 42 to 104 days after delivery Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy through 41 days after delivery

Any human milk feeding vs none around the 2-month WCV (Subgroup Postpartum)

时间窗: 42 to 104 days after delivery

Among those patients who did not discontinue human milk feeding before Tdap vaccine receipt or before the outcome window of interest, any human milk versus formula only or no human milk feeding documented 42 to 104 days after delivery Exposure: Any Tdap 0 to 41 days after delivery Comparator: No Tdap during pregnancy through 41 days after delivery

Exclusive human milk feeding vs none around the 2-month WCV (Subgroup Pregnancy)

时间窗: 42 to 104 days after delivery

Exclusive human milk feeding only versus formula, with or without human milk documented 42 to 104 days after delivery Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy through 41 days after delivery

Exclusive human milk feeding vs none around the 2-month WCV (Subgroup Postpartum)

时间窗: 42 to 104 days after delivery

Among those patients who did not discontinue human milk feeding before Tdap vaccine receipt or before the outcome window of interest, exclusive human milk feeding only versus formula, with or without human milk documented 42 to 104 days after delivery Exposure: Any Tdap 0 to 41 days after delivery Comparator: No Tdap during pregnancy through 41 days after delivery

Any human milk feeding vs none around the 6-month WCV (Subgroup Pregnancy)

时间窗: 148 to 210 days after delivery

Any human milk versus formula only or no human milk feeding documented 148 to 210 days after delivery Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy through 147 days after delivery

Any human milk feeding vs none around the 6-month WCV (Subgroup Postpartum)

时间窗: 148 to 210 days after delivery

Among those patients who did not discontinue human milk feeding before Tdap vaccine receipt or before the outcome window of interest, any human milk versus formula only or no human milk feeding documented 148 to 210 days after delivery Exposure: Any Tdap 0 to 90 days after delivery Comparator: No Tdap 0 to 90 days after delivery

Exclusive human milk feeding vs none around the 6-month WCV (Subgroup Pregnancy)

时间窗: 148 to 210 days after delivery

Exclusive human milk feeding only versus formula, with or without human milk documented 148 to 210 days after delivery Exposure: Tdap on or after 27 gestational weeks (ie, \> 188 days gestation) and less than delivery date Comparator: No Tdap during pregnancy through 147 days after delivery

Exclusive human milk feeding vs none around the 6-month WCV (Subgroup Postpartum)

时间窗: 148 to 210 days after delivery

Among those patients who did not discontinue human milk feeding before Tdap vaccine receipt or before the outcome window of interest, exclusive human milk feeding only versus formula, with or without human milk documented 148 to 210 days after delivery Exposure: Any Tdap 0 to 90 days after delivery Comparator: No Tdap 0 to 90 days after delivery

次要结局

  • Infant growth - Rate of weight gain (Subgroup Pregnancy)(3 - 9 months (To determine predicted values at 9 months of age, measurements up to 12 months were used))
  • Infant growth - Rate of weight gain (Subgroup Postpartum)(3 - 9 months (To determine predicted values at 9 months of age, measurements up to 12 months were used))

研究者

申办方类型
Other
责任方
Sponsor

相似试验